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While it is a common practice to monitor complement levels in patients with systemic lupus erythematosus to aid in flare prediction
and detection, it is unclear if this strategy is helpful in preventing subsequent organ damage. We studied longitudinal complement
levels in 102 SLE patients during a median follow-up of 13.8 years (IQR 7.0, 23.1). Low complement was defined as C3< 0.84 g/L
and/or C4< 0.08 g/L, disease activity by clinical SLEDAI-2K, and organ damage by SLICC-DI. We calculated a time averaged
clinical SLEDAI score (cWAS) and performed multivariate regression models to assess the independent predictive value of low
complement for organ damage at last visit. Hypocomplementemia (HC) was observed in 67% of all patients and was more often
due to low C3 (97%) than low C4 (54%). Compared to patients not developing HC (33%), HC patients were more frequently
positive for anti-dsDNA Ab (72% vs 36%, p < 0 01) and aPL (74% vs 40%, p < 0 01) but HC was concurrently present with
anti-dsDNA Ab in only half the cases. The time-adjusted cWAS scores (1.9 vs 1.2, p = 0 9), frequency (SDI> 0, n = 60), and type
of organ damage accrual were similar for patients with and without HC (OR 1.08, p > 0 20). Intermittent or sustained HC has
no predictive value for damage accrual in SLE or the underlying disease activity over time. This together with significant
discrepancies in the concurrence of low C3, C4, and anti-dsDNA Ab indicates frequent activation of the complement pathway
by other factors than immune complexes in SLE.
1. Introduction
In systemic lupus erythematosus (SLE), defective clearing of
apoptotic material contributes to formation of autoanti-
bodies and immune complexes (ICs). The complement
system is an important host mechanism for the removal of
atypical antigens and IC [1], and in SLE, hypocomplemen-
temia (HC) is considered a serological sign of impending
or ongoing inflammation where complement factors are
“consumed” by tissue bound immune complexes (ICs).
The severity and site of resulting clinical symptoms
together with the frequent need for immunomodulating
drug treatment underwrites the risk of organ damage
accrual and premature mortality in SLE [2–4]. HC is
included in the latest SLICC classification criteria as well
as in disease activity scores for SLE (SLEDAI-2K) [5–9].
The reliability of HC as a serological reflection of underly-
ing inflammation is uncertain as complement levels vary
between healthy individuals [10–12] and complement
synthesis decreases with liver disease and increases during
infection, tissue damage, and hyperglycemia [2, 9, 12–19].
Furthermore, the specific development of anti-C1q Abs in
SLE can dampen or increase complement consumption
and together this may lead to normal complement levels
during active disease [20–23]. Disease activity is strongly
and causally associated with organ damage accrual, and
the accrued amount of organ damage is the most promi-
nent predictor of survival in SLE [24]. As there is limited
data available, we investigated the role of HC as a risk
factor for organ damage accrual in SLE.
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2. Method
We performed a retrospective analysis of prospectively
collected longitudinal data of SLE patients (Table 1). All
participants met American College of Rheumatology classifi-
cation criteria and were followed for a median 10.6 years
(IQR 5.1, 17.8; range 0.3–23.9) with 2-4 routine medical
appointments per annum. Data recorded included clinical
and serological findings, autoantibody status, SLEDAI-2K
score for disease activity, and SLICC-DI damage score [25].
We defined HC as C3< 0.84 g/L and/or C4< 0.08 g/L (by
laser nephelometer) while anti-dsDNA Ab presence was
defined as any anti-dsDNA Ab titer above cutoff (as
assays changed during the study period). We calculated
a clinical SLEDAI (cSLEDAI) score by excluding HC
and anti-dsDNA Ab from overall SLEDAI and then com-
puted a previously validated time-weighted average scores
for clinical SLEDAI (cWAS) to standardize disease activ-
ity across visits with different time intervals [26]. Flares
were classified as mild, moderate, or severe according to
SELENA-SLEDAI flare index [27].
Quantitative variables are described as frequencies
and percentages or median and interquartile range (IQR).
Comparative statistics included the chi-square tests and
Mann-Whitney U test and Spearman correlation coefficients
(Rs). Complement levels were measured approximately twice
a year (median time between measurements was 0.59 years)
(IQR 0.15, 1.55). We therefore performed two separate
analyses of HC: one by defining HC as ever/never and one
by defining HC as episodic (present in <2 subsequent visits)
or chronic, i.e., present during ≥2 subsequent visits (equating
a one year). As both analyses produced essentially similar
results (available on request), we present results for HC
ever only. HC was analyzed as a binary (ever/never present)
and as a continuous predictor (number of times HC
occurred) in age and length of follow-up-adjusted logistic
and time-dependent Cox regression models using SDI> 0
as the dependent variable. All participants provided written
informed consent following approval from the Regional
Norwegian Research Ethics Committee (approval number:
REK 2015/1400).
3. Results
A third of SLE patients (n = 33 3%) sustained normal com-
plement (NC) levels across 387 clinic visits during 7.8 years
(IQR 3.1, 14.8) follow-up (Table 1). Patients who developed
HC (n = 69, 68%) were younger at disease onset (31.0 vs
43.7 years, p < 0 001), more often female (91% vs 79%,
p = 0 06), and had lower waist circumference (69.3 vs
74.2 cm, p = 0 048). Low C3 was significantly more frequent
than low C4 (97% vs 52%, p < 0 01), while simultaneously
low levels were seen in only 48% of HC episodes (Table 1).
Compared to NC patients, HC patients had a higher ever
prevalence of anti-dsDNA Abs (72.5% vs 36.4%, p < 0 01)
and aPL Abs (73.9% vs 39.4%, p = 0 001) but a similar rate
of anti-ENA antibodies: SS-A (51% vs 47%, p = 0 67), SS-B
(21% vs 16%, p = 0 53), RNP (33% vs 30%, p = 0 80), and
Sm (27% vs 23%, p = 0 68). Also, the prevalence of
anti-C1q (9% vs 17%, p = 0 34), antiribosomal-P (13% vs
11%, p = 0 83), or positive Coombs test (16% vs 27%, p =
0 24) was comparable. HC patients were more often
Table 1: Demographic and serological descriptors of SLE patients with and without hypocomplementemia (HC).
NC (n = 33) HC (n = 69) p value
Male 7 (21.2%) 6 (8.7%)
0.076
Female 26 (78.8%) 63 (91.3%)
Age at first visit 43 7 ± 13 7 31 0 ± 12 6 <0.001
Diagnostic delay (years) 2 (IQR 0, 5) 1 (IQR 0, 4) 0.494
Follow-up in years 7 (IQR 3, 13) 12 (IQR 6, 22) 0.017
Smoking ever 20 (66.7%) 39 (59.1%) 0.480
Years smoking 20 (IQR 15, 30) 20 (IQR 13, 26) 0.886
Waist circumference 74 2 ± 13 6 69 3 ± 13 6 0.048
Anti-dsDNA pos. ever 12 (36.4) 50 (72.5) <0.001
Antiphospholipid Ab 13 (39.4) 51 (73.9) 0.001
Lupus anticoagulant pos. 2 (6.1) 12 (17.4) 0.114
aCL-IgG 12 (36.4) 42 (60.9) 0.020
aCL-IgM 8 (24.2) 32 (46.4) 0.032
Low C3 or C4 ever — 69 (100) —
Low C3 +C4 ever — 33 (47.8) —
Low C3 ever — 67 (97.1) —
No. of low C3 episodes — 8 (IQR 4, 14) <0.001
Low C4 ever — 36 (52.2) —
No. of low C4 episodes — 4 (IQR 2, 9) <0.001
Figures indicate median with interquartile range or numbers (%).
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prescribed cytotoxic drugs (50.0% vs 24.2%, p = 0 014)
and prednisone (91% vs 71%, p = 0 004) (Supplementary
Table 1).
The overall annual flare rate for the SLE cohort was 1.00
(IQR 0.50, 1.75) for mild and 0.24 (IQR 0.10, 0.64) for severe
flares, and while all NC and HC patients experienced flares,
more HC patients experienced a severe flare (94% vs 73%)
(Table 2). However, the time averaged disease activity for
the whole disease course was similar for the NC and HC
groups with no association with thrombotic or obstetric
APS for HC patients (Table 2).
The frequency of any organ damage accrual (SDI> 0,
p = 0 910) or the development of severe damage (SDI> 3,
p = 0 94) and amount of organ specific damage accrual
were all similar across NC and HC patients (Table 3) as
was SDI score at last observation (median 2, IQR 1-3, p =
0 9). The predictive value by logistic and Cox regression
modelling for HC for SDI> 0 (OR 1.03) and for HC in com-
bination with anti-dsDNA Ab for renal damage (OR 4.85)
was no longer significant after adjustment for age and length
of follow-up (Table 4 and Supplementary Table 2).
4. Discussion
A third of all patients in this otherwise representative SLE
cohort never demonstrated evidence of hypocomplemente-
mia, which is in line with a reported range of 30-50% patients
maintaining normal C3 and C4 levels throughout their
disease [9, 28–30]. NC patients in this study were older at
SLE diagnosis by ~10 years and had increased waist circum-
ference, which might suggest that increasing age and/or body
mass index (BMI) provide protection against overt HC, e.g.,
by contributing to increased complement synthesis which
upholds serum complement levels even in the face of disease
activity [9, 28, 29, 31, 32].
All patients experienced mild disease flares approxi-
mately once a year and severe flares every three to four years
with flares in HC patients skewed towards higher cSLEDAI
scores due CNS and renal involvement. Despite this, the
similar cWAS scores and flare rates suggest that the burden
of disease activity over time was similar for HC and NC
patients. Some methodological differences aside, this is in
agreement with data from studies by Buyon el al. and Ho
et al. showing no association between low C3 or C4 and
flares, while Ramos-Casals et al. reported equal cumulative
flares rates for HC and NC patients [9, 29, 33]. This lack of
association between HC and disease activity (flares) may
reflect the fact that not all SLE manifestations are immune
complex mediated (Table 2) and suggest that while C3 and
C4 monitoring in general is probably not advantageous or
cost-effective in SLE as a predictor of damage accrual, it
may potentially be clinically useful in a selected group of
patients where significant prior disease activity has occurred
in the context of HC [9, 29, 33–35].
Our study is one of the first to establish that HC is not a
useful predictor of the risk for cumulative or site-specific
organ damage development with multivariate analysis quan-
tifying the risk of damage accrual attributable to HC to no
more than 3-5% over 15 years of follow-up. Gandino et al.
reported similar findings and were unable to link HC (fluctu-
ant or persistent) or the presence of anti-dsDNA Ab to organ
damage during follow-up [28]. Even the clinically feared
combined presence of HC and anti-dsDNA Ab was not a
significant risk factor for organ-specific renal damage after
age adjustment (OR 1.84, p > 0 20). Together, these findings
suggest that much of the damage development in SLE
patients is dependent on mechanisms other than comple-
ment activation. As NC patients received less cytotoxic and
corticosteroid agents in this study but nonetheless developed
similar SDI scores, we can also theorize that in this subgroup
where disease activity was not associated with manifest
HC, treatment may not have been sufficient to prevent
damage accrual.
There was an interesting discrepancy between finding
low C3 (97.1%) and low C4 (52.2%) in this SLE cohort, and
while also observed by others, this remains largely unex-
plained [9, 28]. Low C3 in the face of normal C4 levels does
not fit well with classical IC-induced complement activation
and anti-dsDNAAb, which are considered the key antibodies
for complement activation in SLE were simultaneously
present with low C3 in only a third of all cases. As we also
Table 2: Comparisons of disease activity measures between SLE
patient with normal (NC) and low complement levels (HC).
NC (n = 33) HC (n = 69) p value
WAcS 1.2 (0.65, 3.22) 1.9 (0.9, 3.3) 0.91
Clinical SLEDAI max 8.0 (4.0, 12.0) 13.0 (9.0, 17.0) <0.001
Mild flares (%) 33 (100) 69 (100) —
Severe flares (%) 24 (72.7) 65 (94.2) <0.001
Mild flares per annum 0.8 (0.4, 1.7) 1.1 (0.5, 1.85) 0.12
Severe flares per annum 0.2 (0, 0.5) 0.3 (0.1, 0.8) 0.010
Manifestation
Convulsions 0 (0) 10 (14.5) 0.02
Psychosis 0 (0) 3 (4.3) 0.22
Retinal 1 (3) 1 (1.4) 0.59
Cranial nerve 1 (3) 6 (8.7) 0.31
Vasculitis 6 (18.2) 24 (34.8) 0.07
Cylindruria 4 (12.1) 19 (27.5) 0.06
Proteinuria 6 (18.2) 34 (49.3) <0.001
Arthritis 25 (75.8) 48 (69.6) 0.346
Rash 19 (5.6) 59 (85.5) 0.002
Alopecia 12 (3.4) 43 (62.3) 0.014
Ulcers 8 (24.2) 36 (52.2) 0.008
Serositis 5 (12.1) 25 (23.2) 0.16
Fevers 6 (18.2) 31 (44.9) 0.008
Hemolysis 2 (6.1) 4 (5.8) 0.98
Thrombocytopenia 4 (12.1) 25 (36.2) 0.012
Leucopenia 6 (18.2) 32 (46.4) 0.003
Thrombosis 4 (12.1) 8 (11.6) 0.89
Obstetric APS 4 (12.1) 12 (17.4) 0.49
Figures indicate median with interquartile range or numbers (%). WAcS:
weighted average clinical SLEDAI score (see Methods). Clinical SLEDAI
max: highest cSLEDAI score observed during the disease course; APS:
antiphospholipid syndrome.
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found no role for anti-ENA Ab and anti-C1q Ab in the
risk of developing HC, this supports the assumption that
in a significant proportion of SLE patients, alternate nonim-
mune complex-dependent complement pathway activation
occurs quite frequently [36–39]. Recent experimental find-
ings support a distinctive role for alternative pathway activa-
tion in human SLE with membrane attack complex (MAC)
formation occurring in excess of the typical response to for-
eign pathogens [40, 41]. Although not routinely performed,
including properdin and factor B in serological assessment
could help delineate alternate pathway activation in SLE
[19, 40, 42–44]. We found that HC patients more often car-
ried aCL Ab as also reported by Ramos-Casals et al. [9] but
found no association for HC with thrombotic/obstetric APS
or vascular damage. This is in line with findings by Clowse
et al. who found no difference in aPL Ab prevalence or
pregnancy outcomes across complement status (NC vs HC)
during pregnancy [45]. Finally, the presence of anti-dsDNA
Ab in a large proportion of NC patients confirms that a
significant amount of anti-dsDNA Ab lacks sufficient com-
plement fixing ability, and if at all involved in clinical
manifestations in NC patients, they must do so by pathways
not involving complement [46, 47].
The limitations of this study should be kept in mind.
Firstly, visit frequency was based on the clinical need for
rheumatological consultation whereby patients who achieved
and maintained disease quiescence had less frequent visits.
However, our follow-up routine was in line with current
recommendations [48], and we adjusted for this potential
limitation by utilizing time-adjusted weighted averages of
SLEDAI scores and risk quantification for HC. Our routine
measurement of complement proteins follows a common
Table 3: Comparisons of frequency and severity of damage accrual by SLICC damage index (SDI) between SLE patient with normal (NC) and
low complement levels (HC).
SDI feature
NC (n = 33) HC ever (n = 69)
p value
N (%) Median (CI) N (%) Median (CI)
Any damage 19 (57.6) 41 (59.4) 0.91
Final SDI score 2 (1, 3) 2 (1, 3) 0.82
Final SDI
0 14 (42.4) 28 (40.6)
0.941-3 15 (45.5) 31 (44.9)
> 3 4 (12.1) 10 (14.5)
Organ damage site
Eye 2 (6.1) 1 (1, 1) 3 (4.3) 1 (1, 1) 0.13
Neurological 4 (12.1) 2 (2, 3) 15 (21.7) 1 (1, 2) 0.45
Renal 1 (3.0) 1 (1, 1) 9 (13.0) 1 (1, 2) 0.48
Pulmonary 3 (9.1) 1 (1, 1) 4 (5.8) 1 (1, 1) 0.91
Heart 6 (18.2) 1 (1, 1) 9 (13.0) 1 (1, 2) 0.31
Peripheral vascular 3 (9.1) 1 (1, 1) 4 (5.8) 1 (1, 2) 0.94
MSK 6 (18.2) 1 (1, 1) 15 (21.7) 1 (1, 2) 0.80
Skin 2 (6.1) 1.5 (1, 2) 1 (1.4) 2 (2, 2) 0.24
Gonadal 1 (3.0) 1 (1, 1) 3 (4.3) 1 (1, 1) 0.38
Endocrine 0 (0.0) 0 (0, 0) 1 (1.4) 1 (1, 1) 0.50
Malignancy 6 (18.2) 1 (1, 2) 7 (10.1) 1 (1, 1) 0.98
Table 4: Multivariate analysis of hypocomplementemia (HC) and anti-dsDNA Ab presence as a risk factor for SLICC-DI >0 at last visit by
logistic (yes/no) and time dependent Cox regression (risk increase per episode of HC).
Risk factor HC HC+ anti-dsDNA
Logistic regression OR (CI) OR (CI)
Unadjusted binary exposure 2.03 (0.78, 5.27) 4.42 (1.25, 15.64)
Unadjusted continuous exposure 1.07 (1.00, 1.14) 1.06 (0.98, 1.15)
Cox regression OR (CI) OR (CI)
Unadjusted binary exposure 2.06 (1.13, 3.74) 1.53 (0.82, 2.87)
Unadjusted continuous exposure 0.98 (0.95, 1.01) 0.99 (0.95, 1.03)
Age-adjusted binary exposure 2.38 (1.31, 4.35) 2.04 (1.05, 3.98)
Age-adjusted continuous exposure 0.97 (0.94, 1.00) 0.98 (0.94, 1.02)
Figures indicate odds ratios (ORs) with 95% CI.
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clinical practice, but did not include activation products for
C3 and C4, which in some studies have shown better correla-
tion with especially lupus nephritis [49]. Similarly, we did not
measure activation of alternative pathway activation, which
can directly activate C3 convertase in the face of normal C4
levels. Finally, the homogeneity and clinical settings of this
cohort limit the generalizability of the findings to popula-
tions with a greater degree of diversity. The strength of this
study lies in the long observation period with a complete
dataset for included patients.
5. Conclusions
Hypocomplementemia is unrelated to organ damage accrual
in SLE patients. Discrepancies in the concurrence of low
C3 and C4, disease activity, and anti-dsDNA Ab suggest
that complement activation in SLE often occurs through
pathways not involving immune complexes.
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